Male Infertility – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Male Infertility Market Outlook

Thelansis’s “Male Infertility Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Male Infertility treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Male Infertility Overview

Fertility refers to the ability to achieve a clinical pregnancy, while infertility is a medical condition characterized by the inability to establish a clinical pregnancy within 12 months of regular and unprotected sexual intercourse or due to a person’s impaired reproductive capacity as an individual or with their partner. The causes of male infertility can be broadly classified based on their underlying etiology. These causes include endocrine disorders (typically resulting from hypogonadism), accounting for approximately 2% to 5% of cases; sperm transport disorders (e.g., vasectomy), accounting for 5%. Primary testicular defects (including abnormal sperm parameters without an identifiable cause) account for 65% to 80%, and idiopathic cases (where an infertile male has normal sperm and semen parameters) account for 10% to 20%. Male infertility can also be categorized based on potential medical interventions to aid conception. Untreatable male sterility encompasses conditions such as primary seminiferous tubular failure, Sertoli cell-only syndrome, and bilateral orchiectomy, accounting for 12% of cases. Treatable causes of male infertility, accounting for 18% of cases, include obstructive azoospermia, ejaculatory duct and prostatic midline cysts, gonadotropin deficiency, sexual function disorders, sperm autoimmunity, varicoceles, and reversible toxin effects. Untreatable male infertility, accounting for 70% of cases, includes oligozoospermia, asthenozoospermia, teratozoospermia, and normospermia with functional defects, requiring assisted reproductive techniques for successful reproduction. Various conditions and disorders can contribute to or cause male infertility. Some common causes include adult growth hormone deficiency, 5-Alpha reductase deficiency, androgen receptor gene polymorphisms, brain damage from tumors or trauma, bilateral testicular torsion, celiac disease, chemotherapy, chromosomal abnormalities, and congenital adrenal hyperplasia. Complications often arise from psychological distress, stress, and marital issues. The choice of treatment for male infertility depends on the underlying cause. Common treatment options include medication (administered to enhance sperm production, correct hormone imbalances, treat sperm-affecting infections, or boost testosterone levels), varicocele repair (a minor surgical procedure to address a physical condition that can raise testicular temperature and impact sperm quality), surgery, microsurgical fertilization procedures, and assisted reproductive technologies like in vitro fertilization (IVF).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Male Infertility – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034